NO20021719L - 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament - Google Patents

6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament

Info

Publication number
NO20021719L
NO20021719L NO20021719A NO20021719A NO20021719L NO 20021719 L NO20021719 L NO 20021719L NO 20021719 A NO20021719 A NO 20021719A NO 20021719 A NO20021719 A NO 20021719A NO 20021719 L NO20021719 L NO 20021719L
Authority
NO
Norway
Prior art keywords
drug
preparation
position substituted
substituted indolines
indolines
Prior art date
Application number
NO20021719A
Other languages
English (en)
Other versions
NO20021719D0 (no
NO322746B1 (no
Inventor
Armin Heckel
Gerald Juergen Roth
Rainer Walter
Jacobus Van Meel
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021719(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20021719L publication Critical patent/NO20021719L/no
Publication of NO20021719D0 publication Critical patent/NO20021719D0/no
Publication of NO322746B1 publication Critical patent/NO322746B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20021719A 1999-10-13 2002-04-11 Indoliner, substituert i 6-stilling, og farmasoytisk preparat, samt anvendelse og fremstilling derav. NO322746B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
NO20021719L true NO20021719L (no) 2002-04-11
NO20021719D0 NO20021719D0 (no) 2002-04-11
NO322746B1 NO322746B1 (no) 2006-12-04

Family

ID=26006858

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20021719A NO322746B1 (no) 1999-10-13 2002-04-11 Indoliner, substituert i 6-stilling, og farmasoytisk preparat, samt anvendelse og fremstilling derav.
NO2015009C NO2015009I1 (no) 1999-10-13 2015-03-18 Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO2023033C NO2023033I1 (no) 1999-10-13 2023-09-05 Nintedanib

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2015009C NO2015009I1 (no) 1999-10-13 2015-03-18 Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO2023033C NO2023033I1 (no) 1999-10-13 2023-09-05 Nintedanib

Country Status (42)

Country Link
EP (2) EP2157081A1 (no)
JP (2) JP4021664B2 (no)
KR (2) KR100835546B1 (no)
CN (1) CN100455568C (no)
AR (1) AR026036A1 (no)
AT (1) ATE439342T1 (no)
AU (1) AU781939B2 (no)
BE (1) BE2015C018I2 (no)
BG (1) BG65983B1 (no)
BR (1) BRPI0014735B8 (no)
CA (1) CA2387013C (no)
CO (1) CO5261488A1 (no)
CY (2) CY1110067T1 (no)
CZ (1) CZ301073B6 (no)
DE (1) DE50015711D1 (no)
DK (1) DK1224170T5 (no)
EA (1) EA006080B1 (no)
EE (1) EE05427B1 (no)
EG (1) EG25931A (no)
ES (1) ES2331459T3 (no)
FR (1) FR15C0024I2 (no)
HK (1) HK1052505B (no)
HR (1) HRP20020306B1 (no)
HU (2) HU230416B1 (no)
IL (2) IL148756A0 (no)
LU (1) LU92681I2 (no)
ME (1) MEP45408A (no)
MX (1) MXPA02002799A (no)
MY (1) MY127956A (no)
NL (1) NL300725I2 (no)
NO (3) NO322746B1 (no)
NZ (1) NZ518489A (no)
PE (1) PE20010671A1 (no)
PL (1) PL207445B1 (no)
PT (1) PT1224170E (no)
RS (1) RS51013B (no)
SA (1) SA01210704B1 (no)
SI (1) SI1224170T1 (no)
SK (1) SK287312B6 (no)
TW (1) TWI268922B (no)
UA (1) UA75054C2 (no)
WO (1) WO2001027081A1 (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
EP1401413B1 (en) 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
DE60212627T2 (de) 2001-06-29 2007-06-14 Ab Science Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung von entzündlichen Krankheiten
WO2003027102A1 (en) * 2001-09-27 2003-04-03 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
WO2009071523A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Process for the manufacture of an indolinone derivative
DK2293795T3 (en) 2008-06-06 2015-10-19 Boehringer Ingelheim Int Pharmaceutical combination.
TW201011002A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
IN2014DN06869A (no) 2012-01-26 2015-05-22 Angion Biomedica Corp
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US9642851B2 (en) 2012-12-06 2017-05-09 Kbp Biosciences Co., Ltd. Indolinone derivative as tyrosine kinase inhibitor
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
KR20180128390A (ko) 2015-12-24 2018-12-03 레스피버트 리미티드 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
CA3017308A1 (en) 2016-03-08 2017-09-14 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
JP2019511547A (ja) 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
JP2019523225A (ja) 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブおよびピルフェニドンによる治療開始を決定するためのｅｃｍバイオマーカーの使用
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US10159660B2 (en) 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
CA3079299A1 (en) 2017-10-23 2019-05-02 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019097112A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
EP3860976A1 (en) * 2018-10-05 2021-08-11 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
WO2022158956A1 (ko) 2021-01-25 2022-07-28 주식회사 나이벡 섬유화 예방 및 치료용 펩타이드
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (no) * 1956-06-08
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2201266T3 (es) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited Inhibidores del espesamiento de la capa intima.
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
YU26602A (sh) 2004-11-25
KR100835546B1 (ko) 2008-06-09
HUP0204587A2 (en) 2003-05-28
NO20021719D0 (no) 2002-04-11
PE20010671A1 (es) 2001-06-28
SI1224170T1 (sl) 2009-12-31
IL148756A (en) 2007-10-31
FR15C0024I2 (fr) 2016-08-26
NO2023033I1 (no) 2023-09-05
NO322746B1 (no) 2006-12-04
PL207445B1 (pl) 2010-12-31
LU92681I2 (fr) 2015-05-18
NO2015009I2 (no) 2015-03-18
EG25931A (en) 2012-10-24
FR15C0024I1 (no) 2015-04-17
CY1110067T1 (el) 2015-01-14
NL300725I2 (nl) 2017-07-13
EA006080B1 (ru) 2005-08-25
BRPI0014735A (pt) 2002-07-16
AR026036A1 (es) 2002-12-26
DK1224170T3 (da) 2009-12-07
JP2007302697A (ja) 2007-11-22
EP1224170A1 (de) 2002-07-24
BE2015C018I2 (no) 2019-10-23
CA2387013C (en) 2009-12-29
DK1224170T5 (en) 2018-01-22
HK1052505A1 (en) 2003-09-19
EE05427B1 (et) 2011-06-15
SK6462002A3 (en) 2002-08-06
EP1224170B9 (de) 2017-11-22
PT1224170E (pt) 2009-10-01
BRPI0014735B8 (pt) 2021-07-06
UA75054C2 (uk) 2006-03-15
HRP20020306A2 (en) 2003-10-31
KR20070095996A (ko) 2007-10-01
CN1391557A (zh) 2003-01-15
NZ518489A (en) 2005-05-27
SK287312B6 (sk) 2010-06-07
MXPA02002799A (es) 2003-02-27
BG65983B1 (bg) 2010-08-31
KR20020038949A (ko) 2002-05-24
ES2331459T3 (es) 2010-01-05
SA01210704B1 (ar) 2006-12-05
EP1224170B1 (de) 2009-08-12
HUP0204587A3 (en) 2004-07-28
CY2015009I2 (el) 2016-12-14
CA2387013A1 (en) 2001-04-19
JP4021664B2 (ja) 2007-12-12
EP2157081A1 (de) 2010-02-24
TWI268922B (en) 2006-12-21
EE200200197A (et) 2003-06-16
CZ301073B6 (cs) 2009-10-29
RS51013B (sr) 2010-10-31
JP2003511441A (ja) 2003-03-25
HUS1600022I1 (hu) 2017-02-28
BRPI0014735B1 (pt) 2012-07-10
CZ20021410A3 (cs) 2002-07-17
EA200200380A1 (ru) 2002-10-31
CN100455568C (zh) 2009-01-28
HK1052505B (zh) 2009-06-26
HRP20020306B1 (en) 2010-09-30
CO5261488A1 (es) 2003-03-31
AU781939B2 (en) 2005-06-23
IL148756A0 (en) 2002-09-12
LU92681I9 (no) 2019-01-03
WO2001027081A1 (de) 2001-04-19
PL355433A1 (en) 2004-04-19
DE50015711D1 (de) 2009-09-24
KR100857734B1 (ko) 2008-09-10
MEP45408A (en) 2011-02-10
HU230416B1 (hu) 2016-05-30
BG106587A (bg) 2003-01-31
NO2015009I1 (no) 2015-03-30
ATE439342T1 (de) 2009-08-15
CY2015009I1 (el) 2016-12-14
AU1023301A (en) 2001-04-23
MY127956A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
NO20021719L (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
DK1218341T3 (da) Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20021689L (no) 5-leddede heterocykliske derivater, fremstilling derav og anvendelse som medikamenter
DK1953162T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20025879D0 (no) Acylfenylureaderivater, fremgangsmåte for fremstilling derav og deres anvendelse som et legemiddel
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
NO20014603L (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20014702D0 (no) Diarylderivater og deres anvendelse som medikamenter
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20024749L (no) Indolin-2-on-derivater, deres fremstilling og anvendelse som ocytocinreseptor-ligander
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1230230T3 (da) Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
NO20023146L (no) Substituerte fenyl-piperazinderivater, deres fremstilling og anvendelse
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1523473T3 (da) Indolinderivater substitueret i position 6, deres fremstilling og anvendelse som lægemiddel.
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
DK1157020T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-oler, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
NO20001782L (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1235809T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
NO20015617L (no) Spiroimidazolderivater, deres fremstilling, deres anvendelse og farmasöytiske preparater som innbefatter slike derivater
NO20020404D0 (no) Streptograminderivater, deres produksjon og forbindelser derav

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: VARGATEF, NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201

Spc suppl protection certif: 2015009

Filing date: 20150318

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB, TAUTOMERE OG SALTER DERAV, SPESIELT NINTEDANIB OG FYSIOLOGISKE AKSEPTABLE SALTER DERAV, SPESIELT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954-001-004 20141201

Spc suppl protection certif: 2015009

Filing date: 20150318

Extension date: 20251009

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201

Spc suppl protection certif: 2023033

Filing date: 20230905